Repligen Q1 revenue $206.4M (+45% YoY); lowers FY2022 revenue guidance on COVID decline

REPLIGEN CORP

2022-Q1 EPS reported $0.81 revenue$206,400,000

Record Q1 revenue of $206.4M (+45% YoY); GAAP EPS $0.81, adjusted EPS $0.92.
Base business grew 37% YoY; gene therapy revenue up >100%.
FY2022 revenue guidance lowered to $770-800M (from $800-830M) due to lower COVID demand.
Base business revenue growth guidance raised to 24%-31% (from 20%-22%).
Cash $584.6M at quarter end; gross margin improved 190 bps to 60.1%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.